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INTRODUCTION

Colorectal cancer (CRC) was once considered a rare disease in sub-Saharan Africa
(SSA), but decades of globalisation has
changed this narrative. Currently, CRC
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is the fifth most common cancer in SSA,
and while CRC incidence and mortality
are decreasing in some high-income countries, rates in SSA are on the rise.1 Because
CRC develops from a benign precursor
polyp over several years, early detection
is critical to either prevent malignancy or
detect it at an early stage when it is highly
curable. Moreover, curative surgery has
been shown to improve survival in a SSA
setting.2 Unfortunately, more than 60%
of patients in SSA present with stage 4
CRC with a <1% 5 year survival rate.3–5
In contrast, almost 40% of patients in the
USA present with stage 1 CRC, resulting
in a 5-year survival rate of 90%.6 7 Widespread population-
based CRC screening
programmes and tools (eg, faecal immunochemical test (FIT), colonoscopy) have
improved early detection in high-income
specific data, tools
countries, but SSA-
and screening programmes are currently
lacking. There is an urgent need to
develop more efficient approaches to
CRC screening and early detection that
do not rely heavily on trained healthcare
personnel or specialised resources (eg,
endoscopy, pathology), which are often
scarce in low- and middle-income countries (LMICs).
Recent technological advances and
developments in artificial intelligence (AI)
and machine learning (ML) methods have
the potential to transform global health,
particularly for early detection and diagnosis of CRC in SSA. Researchers are
collecting enormous volumes of data, and
while data science applications are largely
underdeveloped in Africa, many enabling
factors are already in place. Developments
in cloud computing, substantial investments in digitising health information,
and robust mobile phone penetration
have poised many places in SSA with the
Waljee AK, et al. Gut July 2022 Vol 71 No 7

necessary basics to initiate meaningful AI/
ML applications.8 Businesses in SSA have
already embraced technological change,
income
countries
leapfrogging
high-
in the proliferation of mobile banking
(eg, M-
PESA - one of the first mobile
banking system for those with limited
access or no access to banks in Africa.).9
Furthermore, intergovernmental agencies have convened high-profile meetings
discussing the development and democratisation of AI solutions to address
specific global challenges.10 11 The United
Nations has highlighted the centrality of
AI to achieve its Sustainable Development Goals.2 The National Institutes of
Health in the United States has invested
about US$74.5 million over 5 years to
advance data science, catalyse innovation
and spur health discoveries across Africa
under its new Harnessing Data Science for
Health Discovery and Innovation in Africa
I Africa) programme.11 Given these
(DS-
resources and investments, the impact of
AI/ML applications on healthcare in SSA
is imminent.
Herein, we discuss how AI/ML tools
could be leveraged to conduct population-
based surveillance and improve the early
diagnosis and prognosis of CRC in SSA.
We highlight limitations to the currently
available CRC screening programmes and
tools in the SSA setting and provide two
examples of potential AI/ML approaches:
(1) Multianalyte Assays with Algorithmic
Analysis (MAAA) for population-
based
surveillance and early detection and (2)
pattern recognition and computer vision
algorithms to guide diagnostic recommendations and prognosis. While CRC is
the use case, we also discuss how current
initiatives around data science capacity
in Africa offer a platform to scale such
AI-based solutions to other potential high
impact areas such as maternal, newborn,
and child health and the growing burden
of non-communicable diseases (eg, other
cancers, diabetes, cardiovascular disease)
in Africa. Lastly, we highlight how these
innovative solutions have the potential to impact health outcomes in high-
income countries through reciprocal
innovation.12–15

LIMITATIONS TO CURRENT CRC
SCREENING TOOLS IN SSA

Screening programmes and policies
around CRC prevention and detection
are lacking in SSA. Furthermore, data
on disease aetiology and prevalence
are sparse, leaving practitioners with a
limited knowledge base on the disease
in their communities and inadequate
   1259
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AI AND ML APPROACHES
MAAA as a population-based
surveillance and early detection tool
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Laboratory studies, such as complete
blood counts (CBC) and comprehensive
metabolic panels (CMP), are standard
diagnostic tests ordered by clinicians,
even in LMICs. These tests often contain
subtle diagnostic clues; however, interpretation of laboratory studies is routinely
subject to human error. Presymptomatic longitudinal CBC patterns may be
imperceptible to clinicians but would be
readily detectable by statistical algorithms
or ‘prediction models,’ often referred to
as Multianalyte Assays with Algorithmic
Analysis (MAAA).32 Currently, proprietary
Figure 1 Identification of colon cancer in a digital H&E-stained tissue section of colonic
adenocarcinoma. (A) image of colon cancer from a digital slide. (B) a vector was created to identify MAAA exist that were built and validated
in high-
income countries; these MAAA
only the malignant glands, and (C) an additional vector was created to recognise only the stroma.
use CBC and demographic data to identify
(D) Boolean logic was used to determine the malignant glands, and the stroma was subtracted
33–36
Similarly,
out. This approach could assist pathologists in identifying small foci of invasive glands or small foci patients at high risk of CRC.
we
have
developed
a
MAAA
prediction
of tumour present in blood and lymphatic vessels, which might be otherwise overlooked. Figure
model in a US cohort using longitudinal
copyright Hipp et al,50 licensed under CC-BY 2.0 (https://creativecommons.org/licenses/by/2.0/).
and single timepoint laboratory studies
and patient characteristics (accepted to
access to evidence-
based tools for population) with more than half of its
Digestive Disease Week 2022). Initially, we
screening and early detection. These population <25 years of age.22
set out to develop and compare multiple
limitations are understandable given
Currently, several modalities exist
MAAA to predict luminal GI tract cancers
the burden of infectious diseases that for CRC screening and early detecin a retrospective cohort of patients
has historically afflicted SSA. However, tion. Colonoscopy can be used for
(n=1 48 158 with 1025 GI tract cancers)
as SSA experiences the epidemiolog- CRC detection and intervention (eg,
who had at least 2 CBCs within 2 years.
ical shift from infectious diseases to polyp removal), but SSA has limited
Predictor variables included age, sex, race,
non-
communicable diseases, such as endoscopic services. Recent data from
body mass index, individual components
23
CRC, the aetiology of the disease and Mwachiro et al reported an overall
of the CBC and the CMP. To incorporate
the solutions to address the emerging endoscopy capacity in East Africa of
longitudinal features, summary statistics
CRC epidemic require SSA-
specific 1.2 endoscopists, 1.2 gastroscopes and
data and approaches. Extrapolation 0.9 colonoscopes per 100 000 people— were calculated for each subject’s particof cancer screening recommendations values 1% to 10% of that of resource- ular part of the CBC (ie, maximum,
from high-
income countries to SSA is rich countries. Non-invasive screening minimum, slope and total variation). Data
often inappropriate due to differences tests include faecal occult blood testing, were split into 70% training and 30%
in demographics, disease epidemiology FIT and stool-
b ased DNA tests17 24; validation sets for analysis. For the 3-year
and resources. For example, the average however, widespread adoption of stool- prediction of GI tract cancers, the longiturisk screening for CRC is typically based approaches remains suboptimal dinal random forest model performed the
recommended at age 50; however, the in both high-i ncome countries as well as best with an area under the receiver operUS Preventive Services Task Force, the SSA. 25–28 In addition, questions about ator curve (AUROC) of 0.750 (95% CI
American Cancer Society and the US the impact of high ambient tempera- 0.729 to 0.771) and Brier score of 0.116,
Multisociety Task Force on Colorectal ture and endemic parasitic infection compared with the longitudinal logistic
Cancer have recently recommended as well as the practicality and cost- regression with an AUROC of 0.735 (95%
lowering it to 45 years.16–18 In SSA, effectiveness of these approaches in CI 0.713 to 0.757) and Brier score of
estimates from available data indicate SSA remain.29–31 Regardless, endoscopy 0.205. The longitudinal logistic regression
that 19%–38% of CRC diagnoses are is still needed for diagnosis and prog- and random forest models outperformed
in persons <40 years of age—a stark nosis. Thus, early detection strategies the single timepoint logistic regression at
contrast to the 1%–7% reported in high- that target those at the highest risk 3 years, with an AUROC of 0.683 (95%
income countries.19–21 The higher risk of benefit from these limited services are CI 0.665 to 0.701). These findings are
the early development of CRC, coupled paramount. With growing investments limited in that the MAAA predicts GI tract
with the recent lowering in screening in technologies (eg, electronic health cancer, not CRC specifically, although just
age, highlight the evolving epidemi- records and cloud computing) in SSA, over half of patients with GI tract cancers
ology of CRC in younger adults and the existing and expanding infrastruc- had CRC (53.5%, n=548/1025). To date,
the need to tailor screening approaches ture can be leveraged to employ novel this approach has not been validated in
to capture this cohort, particularly in AI/ML methods to develop and validate a low resource setting or SSA, where
SSA. There is urgency to address this surveillance tools that identify popula- demographics and disease aetiology may
need given that Africa’s population is tions at highest risk for CRC in a more differ, and longitudinal laboratory studies
projected to double by 2050, reaching individualised or precise manner, as may not be readily available. In addition,
CBC and CMP baselines likely vary across
nearly 2.5 billion (23% of the global described below.

Leading article

Figure 2 Summary of analysis workflow for identifying histological determinants of malignant
transformation and disease grade. Step 3 uses a support vector machine classifier, but any
classifier can be used (eg, random forest). Figure copyright Powell et al,52 licensed under CC-BY
2.0 (https://creativecommons.org/licenses/by/2.0/). BIC, Bayesian information criterion; OS, overall
survival; SVM, support vector machine.
genetically diverse populations and can be
influenced by the prevalence of infectious
and chronic conditions, including other
malignancies and genetic conditions such
as sickle-
cell disease that have distinct
prevalence in different populations. While
these previous studies provide proof of
concept for the development of MAAA
for CRC screening in SSA, it would be
essential to develop and compare models
that incorporate longitudinal and cross-
sectional laboratory data to determine the
performance and optimal specificity or
sensitivity for the target populations.
CRC is particularly amenable to
MAAA-
guided early detection strategies for multiple reasons. First, CRC is
highly curable when diagnosed at an early
stage.6 Second, CRC is highly vascular
and can produce very subtle chronic
occult blood loss, which could be detected
before symptoms develop using data from
routine longitudinal CBCs and CMP
Waljee AK, et al. Gut July 2022 Vol 71 No 7

and ML-
based methods.34 35 37 Indeed,
patients in SSA tend to present with late-
stage CRC, being diagnosed after clinical
presentation with symptoms.6 7 Third,
MAAA can be tailored to the local needs.
For example, positive predicted values
and negative predicted values of MAAAs
can be adjusted to maximise sensitivity
or specificity based on target populations
(eg, age groups), resource availability, or
sequential testing approaches (eg, MAAA
and then FIT). Similar work has been done
in other settings where resources were
limited, particularly during COVID-
19,
where FIT-
based quantitative screening
thresholds were used to direct patients
for endoscopic services.38 39 Finally,
the costs and resources required to the
patient and healthcare facility/provider
are significantly less since it uses routine
labs collected in various clinical settings.
This is particularly relevant given the
significant improvements in laboratory

AI-based algorithms in pathology for
early diagnosis and prognosis

After screening, accurate and timely diagnosis is critical to identifying appropriate
treatment plans in cancer management.
While CRC is diagnosed via clinicopathological assessment by a pathologist, the
availability of such expertise and resources
in SSA are minimal. A 2012 survey of 33
African countries found that 31 (94%)
had fewer than one pathologist for every
500 000 people, and many had fewer
than one pathologist for every 1 million
people.48 These values are 10% in high-
income countries, like the USA, which
had one pathologist for every 20 600
people in 2010. In addition to the lack of
trained pathologists, access to immunohistochemical (IHC) reagents required for
accurate and definitive diagnosis remains
a significant hurdle. Unlike in infectious
diseases, H&E-stained slides do not often
suffice to make a precise diagnosis. Thus,
a lack of efficient and reliable pathology
services leads to delays and inaccurate
reporting of results, which contributes
to patients receiving inappropriate treatment. Patients may be prescribed medications that are expensive yet ineffective and
sometimes even harmful in treating their
1261
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medicine in Africa driven by efforts to
combat HIV/AIDS. In addition to developing a competent workforce and innovative quality improvement programmes
that saw more than 1100 laboratories
enrolled and 44 accredited to international standards, several regional laboratory networks have also been established
to support programme scale-
up and
disease surveillance.40 This infrastructure
can support robust healthcare systems
and combat emerging continental and
global health threats, like CRC and other
cancers. Although, despite available diagnostic testing, studies have shown that
they are not optimally used in managing
patient care, and tools to bridge the diagnostic–treatment divide are needed.41 42
MAAAs offer one approach to help bridge
this gap and can be coupled with simple
based tools (eg, nomograms) to
paper-
more complex mobile app-based tools or
lightweight, field-deployed (cloud-based)
Laboratory Information Systems designed
for use in LMICs.43 44 In addition to the
use of MAAAs as a tool for CRC diagnosis, the approach could be adapted
for the prediction of CRC prognosis and
treatment outcomes as both the CBC and
CMP profiles of patients have been associated with disease stage, metastasis and
treatment outcomes.45–47
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OPPORTUNITIES

•
•
•
•
•

Need for Better Data
Data Digitization
Model Bias and Data Missingness
Equitable Access
AI Literacy

• FAIR Principles (Findable, Accessible, Interoperable, Reusable) – Registries;
Standardization of Data; Open Data Science Platforms
• Affordable Infrastructure – Cloud Computing; Equipment
• Workforce Capacity Building – Training Programs; Faculty Development

Ethical, Legal, and
Social Implications

•
•
•
•

Governance
Local Regulations
Privacy
Fairness/Justice

• Develop Standards and Policies
• GDPR Compliant Cloud-Based Systems
• Data Protection and Security – Blockchain Technology; Access Controls; Secure
Multi-Party Computation, Enclaves; Synthetic Data, Federated Learning;
Encryption
• Public Engagement – Needs Assessment; Co-Design Implementation Strategies

Dissemination

•
•
•
•

Adoption and Scalability
Access to High Quality Care
Implementation
Key Stakeholder Engagement

•
•
•
•

Sustainability

• Infrastructure (trained workforce, • Infrastructure Capacity Building – Automating Processes, Biobank Services
• Impact Evaluations
equipment, electricity, internet)
• Reciprocal Innovation
• Funding
• Multi-Sectorial Partnerships and Engagement

Data Management
and Analysis

Decision Support Systems and Care Pathway Development
User-Centered Design
Implementation Science and Evaluation Strategies – Rapid Cycle Evaluations
Stakeholder Engagement
o Community and Patient – CABs; Patient Education
o Policy Makers – Policy Briefs; Targeted Communications
o Practitioners – Outreach with NGOs, CBOs

Figure 3 Examples of challenges and opportunities for leveraging AI-based approaches in sub-
Saharan Africa. AI, artificial intelligence; CAB, community advisory board; CBO, community-based
organisation; NGO, non-governmental organisations.
cancer type. Recent advances in AI-based
computer vision and pattern recognition
algorithms that use routine H&E-stained
whole slide imaging offer transformative
tools well suited for early cancer diagnosis
and prognosis in SSA.
Pattern recognition algorithms aim
to detect abnormalities in cell and tissue
samples faster, more accurately and more
consistently. In clinical care, these tools
can assist pathologists in diagnostic recommendations by pre-screening an image and
identifying potentially problematic areas,
including subtle features that may not be
readily apparent to the eye. For example,
Invariant
the VIPR (Vectorising spatially-
Pattern Recognition) algorithm and software is a fully operational application suite
developed by the Data Visualisation Core
of the National Institute of Diabetes and
Digestive and Kidney Diseases’ Kidney
Precision Medicine Project.49–51 VIPR uses
semisupervised and unsupervised, pixel-
level classification of digital whole slide
image content, which allows for extremely
high-throughput analysis of entire libraries
of whole slide imagery. VIPR differs from
conventional pattern recognition software by basing its core search on a series
of concentric, pattern-
matching rings
rather than the more typical rectangular
or square blocks. This approach takes
advantage of the continuous symmetry
of the rings, allowing for the recognition
of features independent of rotation. By
making use of massively parallel computational platforms to realise necessary
speed and performance, VIPR performs
direct integration of vectorised image
data with other classes of patient data (eg,
lab values, clinical phenotypic features,
1262

clinical course, outcomes), thus allowing
for a more global assessment of health
status and biological potential of any given
malignancy. The pixel-level precision and
consistency for whole slide image classification exceeds what is possible using
subject matter expertise alone. Moreover,
it has demonstrated high reproducibility
across different fields of view of a single
slide, different slides in the same case, and
different cases entirely.49–51
The VIPR tool was initially developed to
interrogate tissue from patients with acute
kidney injury or chronic kidney disease
to define disease subgroups and identify
critical cells, pathways, and targets for
novel therapies. It has since proved to be
highly effective for cancer detection and
classification in colon cancer (figure 1)
as well as haematology, breast cancer and
lymphoma.49–51 Because VIPR has been
designed as a turn-key system for automated objective assessment of H&E slides
for disease diagnosis, it is suitable for
deployment in settings where pathologists
alone can effectively incorporate the tool
into clinical workflow, without the need
for the immediate response from an image
analysis expert. Once histologically distinct
regions are identified or ‘prescreened,’
image analysis algorithms can then be used
to mine individual regions and aggregate
them to predict malignant transformation,
as described below.
Following disease detection from histopathology, disease grading and IHC classification is critical to classifying various
subtypes of cancer and thus determining
appropriate treatment. Another rapidly
advancing area is the use of computer
vision and deep learning to digitally

phenotype histological slides to better
understand treatment response and
survival.52 These algorithms can complement the clinical interpretation of diseased
tissue in which the underlying diagnosis
has already been made. This approach was
employed in an image analysis and data
mining pipeline to identify histological
features capable of differentiating between
cancer and non-
cancer lesions and the
potential in
malignant transformation-
gliomas (figure 2).52 Using whole slide
imaging data from the Cancer Genome
Atlas and companion clinical data for these
specimens, we assessed the prognostic
relevance of these histological discriminants.53 54 Histopathology image-derived
measurements, such as cell morphologies,
spatial patterns of cellular organisation, in
combination with a bag-of-words (BoW)
approach53 55 was used to identify tissue
subregions that have visually distinct properties (eg, nuclear morphology, patterns of
spatial organisation) and were associated
with time-to-malignant transformation.
The BoW approach is akin to clustering
image subregions (ie, patches) derived
from the whole slide image of the tissue.
Importantly, this dictionary achieved an
AUROC (through cross-validation) of 0.76
to discriminate surrogates of malignant
transformation. While this approach was
developed in glioma, it offers one potential strategy to incorporate image features
derived from routine H&E-stained slides
into prognostic, predictive models of
other cancers, such as CRC. In addition
to the above approach, deep learning algorithms leveraging popular architectures,
such as Reset, VGGNet, and Inception,
are also being adopted in the context of
cancer prognosis,56 57 providing a path to
a ‘non-
feature-
engineering’ approach to
image recognition and content mining. In
tandem with recently developed methods
around feature interpretability,58 these
tools can be incorporated into clinical workflows. It is worth noting that
modern computer vision techniques aim
to adjust for multiple biases in data acquisition, image staining and related artefacts, contributing to the development
and delivery of robust decision support
algorithms.
Digital pathology lab systems and infrastructure are becoming more obtainable
in SSA. For example, the VIPR Software
is open-source, and microscopes that are
small and fully remote-operable, capable
of high-
resolution images have become
more affordable. Also, while these technologies can be computationally expensive
(ie, requiring graphical processing unit
and storage for gigapixel histopathological
Waljee AK, et al. Gut July 2022 Vol 71 No 7
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CHALLENGES
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FUTURE DIRECTIONS

In the era of value-based healthcare, AI/
ML provides opportunities to improve

access to care, reduce wastage, optimise
resource utilisation and provide a mechanism for quality assurance of healthcare
regarding CRC screening, diagnosis and
management. Funding agencies (government, donors or commercial) are more
likely to invest in a system whose outputs
are easily measured and can be bench
marked against available resources. This
is particularly important in SSA were data
driven management of healthcare delivery
is still a challenge. Routine use of AI/ML
tools and their dissemination remains rare
in high-income countries, not to mention
LMICs. Advances in model performance
characteristics have accelerated, but
despite performing well in silo using retrospective data in a research setting, prediction models (ie, using logistic regression

Figure 4 Depiction of the Harnessing Data Science for Health Discovery and Innovation in
Africa (DS-I Africa) programme and exemplar research hub. (A) The four main initiatives are:
(1) Research hubs will apply novel approaches to data analysis and artificial intelligence to
address critical health issues in Africa. (2) Open data science platform and coordinating centre
will provide a flexible, scalable platform for the DS-I Africa researchers to find and access data,
select tools and workflows, and run analyses through collaborative workspaces. It will also deliver
the organisational framework for the direction and management of the initiative’s common
activities; (3) Research training programmes will create multi-tiered curricula to build skills in
foundational health data science, with options ranging from master’s and doctoral degree tracks
to postdoctoral training and faculty development; and (4) The ethical, legal and social implications
(ELSI) projects will address data science issues that present challenges in Africa such as data
privacy and ownership, cybersecurity and sensitivities concerning the use of geospatial information
for research or public health surveillance. (B) Led by the Aga Khan University—East Africa, Kenya
Medical Research Institute-Wellcome Trust Research Programme, and the University of Michigan,
the research hub will implement two research projects around maternal, newborn and child health
as well as mental health, which will be supported by three cores: Admin core, Data Management
and Analysis Core (DMAC) and Dissemination and Sustainability Core (DSC). The Admin Core
will lead the UZIMA-DS researchhub, fostering synergy and integration of all hub components
and partnerships and facilitating participation in DS-I cross-consortium activities. The DMAC will
employ FAIR (Findable, Accessible, Interoperable, Reusable) principles to support the hub’s data
ecosystem through data governance, facilitating data analytics within the projects, and fostering
data sharing and interoperability throughout the greater DS-I Africa consortium. The DSC will
promote engagement with stakeholders to identify sustainable model dissemination pathways
into target communities. Through multisectoral partnerships with government, healthcare and
non-profit sectors, the core will: facilitate the development of best practices and policies with
stakeholders using data-driven approaches to inform guidelines; and promote engagement with
private sectors to explore sustainable commercialisation opportunities and pathways. UZIMA-DS,
UtiliZing Health Information for Meaningful Impact in East Africa Through Data Science.
Waljee AK, et al. Gut July 2022 Vol 71 No 7

or AI/ML-based methods) rarely leave the
exploratory domain for use in the clinical
or community settings. The development
and deployment of AI/ML-based tools in
SSA require addressing existing limitations
in computing infrastructures and a lack of
local data needed to support the creation
of effective models. However, solving
these problems will not automatically
lead to widespread adoption. If we do not
directly address the challenges of dissemination and adoption of these prediction
models in a way that supports social
justice and health equity, data science
approaches will have minimal impact on
the health of individuals and populations.
The issues surrounding the development,
deployment and adoption of AI/ML-based
tools in LMICs, and SSA, have been extensively described elsewhere.59–61 Examples
of some of the challenges and opportunities for leveraging AI-based approaches in
SSA are provided in figure 3.
To address these challenges and increase
the capacity to use and develop data
science approaches in health research and
innovation in Africa, the National Institutes of Health (NIH) recently launched
a new Common Fund Programme:
Harnessing Data Science for Health
Discovery and Innovation in Africa (DS-I
Africa).11 DS-
I Africa builds on prior
investments by the NIH Common Fund
and its partners in the Medical Education
Partnership Initiatives and the Human
Health and Heredity in Africa (H3Africa)
consortium to form a unique continental
ecosystem that could be transformative,
leveraging existing expertise to develop
data tools and applications that can be
shared, adopted, and harmonised globally.
Creating a robust network of partnerships
across the African continent and in the
USA, including numerous national health
ministries, non-
governmental organisations, corporations and other academic
institutions, the DS-I consortium includes
seven research hubs (all of which are led
by African institutions), seven research
training programmes, four projects
focused on ethical, legal and social implications of data science, and an open data
science platform and coordinating centre.
Figure 4 depicts the synergistic initiatives within the DS-I Africa Consortium
and highlights one of the research hubs to
demonstrate how the hub aims to function
as a scalable and sustainable data science
platform in Kenya and within the greater
I consortium. The exemplar hub,
DS-
UtiliZing Health Information for Meaningful Impact in East Africa Through
Data Science (UZIMA-
DS), will address
three critical needs across the translational
1263
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scans), the emergence of cloud computing
in SSA can transform innovation and efficiency around how data are used. Taken
together, one could envision an analytical
pipeline that couples operational pattern
recognition tools with image analysis algorithms for automated and democratised
identification and prediction of CRC from
routine H&E histology images that is scalable. The current development of data
science collaboratives in Africa could also
facilitate the adoption and deployment
of these tools, as well as MAAA-guided
models for early detection and diagnosis
of CRC as outlined below.
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SUMMARY

With the growing resources and investments in AI/ML-based tools in SSA, one
could envision a CRC surveillance and
diagnosis pipeline that employs MAAA
for population-
based surveillance and
pattern recognition and computer vision
algorithms to guide diagnostic recommendations and prognosis. These tools will
need to be tailored to local needs based on
available resources and testing approaches
(eg, sequential testing with MAAA and
then FIT) and key stakeholders will
need to engage in the codesign of widespread implementation strategies (eg,
community-based screening programmes,
practitioner education, health policies).
1264

Future studies are required to compare
the efficacy of these tools to existing CRC
surveillance and diagnosis tools (eg, FIT)
in SSA populations. Furthermore, these
innovative solutions provide opportunities for the adaption and adoption of these
income countries.
approaches in high-
While CRC was used as the use case, these
tools could be expanded to other prevalent and emergent cancers (eg, liver, breast
and cervical) or other non-communicable
diseases that would benefit from lab-based
MAAA and computer vision AI-
based
methods for automated objective assessment of disease diagnosis and prognosis.
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